Sichuan Shenghe Pharmaceutical

Sichuan Shenghe Pharmaceutical is a prominent Chinese pharmaceutical company and a core subsidiary of the Nanjing Shenghe Pharmaceutical Group. Based in Chengdu, the company specializes in the development, manufacturing, and commercialization of chemical drugs, with a strong historical focus on anti-infective agents and a growing presence in oncology. Its commercial success is anchored by market-leading products such as Ornidazole and Gatifloxacin, which are widely used in China for treating anaerobic and bacterial infections. As part of the broader Shenghe R&D ecosystem, the company supports the production of innovative small molecules, including the recently approved EGFR inhibitor Rezivertinib. Sichuan Shenghe operates large-scale, GMP-certified manufacturing facilities that serve as a critical production hub for the group's domestic and international supply chains.